NCT03284268View on ClinicalTrials.gov

Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions
Retinoblastoma, Recurrent
Interventions
GENETIC

VCN-01

VCN-01 intravitreal injection

Trial Locations (1)

08950

Hospital Sant Joan de Déu, Barcelona

All Listed Sponsors
lead

Fundació Sant Joan de Déu

OTHER

NCT03284268 - Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma | Biotech Hunter | Biotech Hunter